Education
About Us
Working with TipRanks
Follow Us
Alumis Inc. (ALMS)
NASDAQ:ALMS
Top Page
Alumis Inc.
(NASDAQ:ALMS)
41Neutral
Positive Factors
Clinical Data
Acceptance of 52-week Phase 2 OLE data for ESK-001 in psoriasis as a late-breaking oral presentation at AAD suggests strong interest and validation in the clinical community.
Market Positioning
Unique market positioning of ESK-001 could seize market share from injectable products, offering an effective oral option with the promise of convenience.
Negative Factors
Investment Priority
Any additional clinical studies for lonigutamab would require the identification of clear clinical differentiation, indicating a lower priority for investment compared to the TYK2i pipeline.
Alumis Inc. (ALMS) vs. S&P 500 (SPY)
Market Cap
$260.61M
Dividend YieldN/A
Average Volume (3M)232.15K
Price to Earnings (P/E)―
Beta (1Y)0.77
Revenue GrowthN/A
EPS GrowthN/A
CountryUS
Employees109
SectorBasic Materials
Sector Strength63
IndustryBiotechnology
Share Statistics
EPS (TTM)-4.47
Shares Outstanding47,222,420
10 Day Avg. Volume139,721
30 Day Avg. Volume232,152
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
Price to Cash Flow (P/CF)-0.80
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
$20.67Price Target Upside331.52% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering4
Alumis Inc. Business Overview & Revenue Model
Company DescriptionAlumis Inc. (ALMS) is a biotechnology company operating in the pharmaceutical sector. The company focuses on developing and commercializing innovative therapies for autoimmune diseases. Alumis leverages cutting-edge research and development to create treatments that improve patient outcomes and address unmet medical needs in the autoimmunity space.
How the Company Makes MoneyAlumis Inc. makes money primarily through the development and commercialization of pharmaceutical products. The company's revenue model is driven by the successful development of its drug pipeline, leading to the commercialization of therapies that address specific autoimmune conditions. Key revenue streams include product sales, licensing agreements, and potential collaborations with other pharmaceutical companies for co-development or distribution of their treatments. Alumis may also receive milestone payments and royalties from partnerships, contributing to its earnings.
Alumis Inc. Financial Statement Overview
Summary
Alumis Inc. is in a developmental stage typical of biotech firms, showing negative profitability with no revenue and significant net losses. The balance sheet suggests moderate leverage, but cash flows indicate heavy reliance on external funding, posing financial risks until revenue streams are established.Income Statement
Alumis Inc. shows negative profitability metrics with no revenue generation, indicating early-stage biotechnology operations. The significant increase in net loss year-over-year reflects heightened operational expenses or R&D costs typical for this industry, without revenue to offset these costs.30
Negative
Balance Sheet
The balance sheet reveals a moderate debt-to-equity ratio, suggesting manageable leverage. However, a reduction in stockholders' equity compared to the previous year indicates potential pressure on financial stability. The equity ratio remains decent, providing a buffer against liabilities.45
Neutral
Cash Flow
Cash flow analysis highlights negative operating and free cash flows, common for a biotech firm in development stages. A positive financing cash flow suggests reliance on external funding to support operations. High cash burn rates pose a risk unless countered by future funding or revenue growth.40
Negative
| Breakdown | ||
| TTM | Dec 2023 | Dec 2022 |
|---|---|---|
| Income Statement | Total Revenue | |
| 0.00 | 0.00 | 0.00 | Gross Profit |
| -1.52M | -1.28M | -250.00K | EBIT |
| -242.26M | -158.17M | -113.85M | EBITDA |
| -239.21M | -156.89M | -113.60M | Net Income Common Stockholders |
| -238.77M | -154.99M | -111.93M |
| Balance Sheet | Cash, Cash Equivalents and Short-Term Investments | |
| 92.86M | 48.95M | 93.07M | Total Assets |
| 0.00 | 89.61M | 108.17M | Total Debt |
| 0.00 | 32.58M | 1.78M | Net Debt |
| 92.86M | -13.42M | -24.04M | Total Liabilities |
| 0.00 | 53.50M | 17.94M | Stockholders Equity |
| 90.23M | 36.11M | 90.23M |
| Cash Flow | Free Cash Flow | |
| -216.62M | -134.47M | -110.13M | Operating Cash Flow |
| -214.04M | -129.97M | -107.72M | Investing Cash Flow |
| -148.88M | 60.47M | -68.75M | Financing Cash Flow |
| 522.09M | 89.68M | 101.63M |
Alumis Inc. Peers Comparison
Overall Rating
UnderperformOutperform
Sector (46)
Financial Indicators
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
78 Outperform | $78.51B | 19.43 | 15.95% | 0.12% | 8.27% | 10.35% | |
75 Outperform | $142.50B | 306.43 | 2.28% | 2.63% | 6.16% | -91.54% | |
75 Outperform | $171.31B | 43.30 | 67.55% | 2.79% | 18.64% | -39.39% | |
64 Neutral | $128.40B | ― | -3.15% | ― | 11.64% | -114.72% | |
48 Neutral | $13.03B | ― | -28.77% | ― | -52.75% | 25.00% | |
46 Neutral | $2.64B | -3.89 | -29.36% | 3.33% | 2.89% | -29.66% | |
41 Neutral | $260.61M | ― | -429.22% | ― | ― | ― |
* Basic Materials Sector Average
Performance Comparison
ALMS
Alumis Inc.
4.79
-7.75
-61.80%
AMGN
Amgen
318.89
51.07
19.07%
GILD
Gilead Sciences
114.43
41.47
56.84%
REGN
Regeneron
718.16
-246.07
-25.52%
VRTX
Vertex Pharmaceuticals
488.34
75.14
18.18%
MRNA
Moderna
33.76
-72.75
-68.30%
Glossary
OutperformA stock rated as "Outperform" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests that the stock is likely to deliver higher returns compared to the average returns of other stocks in the same sector or market index. Investors might consider this stock a good buying opportunity.
NeutralA stock rated as "Neutral" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly attractive nor unattractive for investment. Investors may consider holding onto the stock, as it is not expected to either significantly outperform or underperform the market.
UnderperformA stock rated as "Underperform" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests that the stock may deliver lower returns compared to the average returns of other stocks in the same sector or market index. Investors might consider selling the stock or avoiding it as an investment.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.